egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data

The upgrade accelerates a health system's capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways

ALISO VIEJO, Calif., Sept. 8, 2026 /PRNewswire/ -- egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage patients with untreated heart disease, today announced significant enhancements to its CardioCare platform, which is used by more than 80 structural heart and cardiovascular programs nationwide.

Built directly from customer feedback, the improvements give care teams a simpler view of the guideline-directed pathway CardioCare already builds for patients. As part of the update, patient details are organized by pathology, summarizing the key findings from the EMR, echo reports and ECG reports on a single patient review screen — so clinicians can review a patient without digging through multiple places in the chart. The update also adds severity-based patient lists and a new customizable "My CardioCare" home page. The UI is arranged the way clinical teams already think about disease, with meaningful events such new echocardiograms or admissions surfaced automatically.

"This is a real step forward for the platform. Everything we rely on has been there, but it's now faster to get to and easier to access. Having smoother access to the clinical context, which is usually buried deep in notes and reports, helps us prioritize which charts we review first and makes it easier to make sure the patients we send forward are appropriate," said Rachel Bates, a general cardiology and interventional cardiology coordinator at Buffalo General Hospital. "egnite makes a real effort to keep the platform user-friendly for providers, and they consistently ask for feedback."

The stakes are real. Despite more than a decade of CV treatment innovation, research has found that many patients remain untreated even though they meet guideline criteria for intervention. According to egnite's 2023 Structural Heart Disease Benchmarking Report, "National Treatment Rates Remain Low Despite Proven Therapies," the average symptomatic severe aortic stenosis (ssAS) 12-month treatment rate is 58% — meaning 42% of severe, symptomatic AS patients remain untreated within a year of diagnosis. AS is one heart condition - egnite's CardioCare was custom built to help solve the challenges along a range of conditions including Heart Failure, Atrial Fibrillation, Mitral Valve, and Tricuspid Valve disease.

Cardiovascular data is generated faster than most health systems can act on it — echo findings, labs, notes, encounters, admissions, and referral activity—each living in a different system on a different timeline, much of it locked in unstructured reports and clinical notes. CardioCare pulls that data together and applies its own AHA-ACC based clinical logic—built specifically for cardiovascular disease—on top of it. The information is then displayed in user-friendly, clinically relevant, and customizable views for clinicians to act upon.

"We take pride in helping our hospital partners surface the patients who need their attention — at a scale no team could manage chart by chart. This update makes that even easier for the hundreds of specialized CV users on CardioCare today," said Kahla Verhoef, Chief Operating Officer at egnite Health. "As heart programs take on a widening range of diseases, CardioCare is built to bring those patients to the team's attention and support them along the full guideline-directed treatment pathway."

About egnite, Inc.
egnite, Inc. is a rapidly growing cardiovascular intelligence company that uses AI and clinical workflow integration to help health systems identify and manage patients with untreated cardiovascular disease and provide de-identified real-world data for Life Sciences and research. egnite partners with leading hospitals and life sciences organizations to improve patient identification, accelerate research, and support better cardiovascular outcomes at scale. The company is headquartered in Aliso Viejo, California.

For more information, visit www.egnitehealth.com.

* The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of cardiovascular diseases.

SOURCE egnite, Inc.